8-K: Penumbra Inc. Reports Strong Third Quarter Growth Driven by U.S. Thrombectomy Sales

Penumbra, Inc. announced an 11.1% increase in revenue for the third quarter of 2024, driven by strong growth in its U.S. thrombectomy business.

Summary

• Penumbra, Inc. reported a total revenue of $301.0 million for the third quarter of 2024, which is an 11.1% increase compared to $270.9 million in the same quarter of 2023.
• The company's U.S. thrombectomy revenue reached $162.1 million, showing a significant 21.2% increase year-over-year and a 5.4% increase compared to the second quarter of 2024.
• The U.S. VTE (venous thromboembolism) franchise experienced substantial growth, increasing by 32% compared to the third quarter of 2023.
• Global thrombectomy product sales grew by 14.0% to $204.1 million, while global embolization and access product sales increased by 5.5% to $96.9 million.
• The company's gross profit was $200.3 million, representing 66.5% of total revenue, compared to $177.7 million, or 65.6% of total revenue, in the third quarter of 2023.
• Income from operations was $35.4 million, and non-GAAP income from operations was $40.3 million for the third quarter of 2024.
• Net income was $29.5 million, with an adjusted EBITDA of $56.7 million, resulting in a net income margin of 9.8% and an adjusted EBITDA margin of 18.8%.
• Penumbra has reiterated its full-year 2024 revenue guidance to be between $1,180.0 million and $1,200.0 million.
• The company now expects its U.S. thrombectomy franchise to grow by 24% to 25% year-over-year, an increase from the previous guidance of 23% to 25%.

Sentiment

Score: 8

Explanation: The document presents a strong financial performance with significant growth in key areas, particularly the U.S. thrombectomy business. The company has also increased its full-year growth expectations, indicating a positive outlook. However, there are some risks and negative aspects, such as the decrease in international revenue and one-time expenses, which temper the overall sentiment.

Positives

• Penumbra experienced strong revenue growth in the third quarter of 2024, with an 11.1% increase year-over-year.
• The U.S. thrombectomy business showed significant growth, with a 21.2% increase in revenue compared to the same quarter last year.
• The U.S. VTE franchise demonstrated exceptional growth, increasing by 32% year-over-year.
• The company's gross profit margin improved to 66.5% from 65.6% in the same quarter of the previous year.
• Penumbra achieved a solid adjusted EBITDA margin of 18.8% for the quarter.
• The company has increased its full-year growth expectations for the U.S. thrombectomy franchise.

Negatives

• International revenue decreased by 1.9%, or 2.5% in constant currency, compared to the third quarter of 2023.
• Total operating expenses were $164.9 million, which included $5.0 million of one-time expenses related to the wind down of the Immersive Healthcare business.

Risks

• The company faces risks related to sustaining profitability and generating positive cash flows.
• There are risks associated with introducing and marketing new products effectively.
• The company is subject to significant competition in the medical device market.
• There are risks related to maintaining satisfactory pricing and margins.
• Manufacturing difficulties and product defects or failures could impact the company's performance.
• Unfavorable outcomes in clinical trials could negatively affect the company.
• Fluctuations in foreign currency exchange rates could impact financial results.
• Potential adverse regulatory actions could pose a risk to the company.
• The company faces risks related to acquisitions, mergers, dispositions, joint ventures or investments.

Future Outlook

The company reiterates its full-year 2024 revenue guidance to be in the range of $1,180.0 million to $1,200.0 million and expects the U.S. thrombectomy franchise to grow 24% to 25% year-over-year. They also expect gross margin and non-GAAP operating margin expansion.

Management Comments

• Management believes the non-GAAP financial measures disclosed in this press release are useful to investors in assessing the operating performance of our business and provide meaningful comparisons to prior periods.
• Management considers the change in constant currency revenue as a useful metric as it provides an alternative framework for assessing how our underlying business performed excluding the effect of foreign currency rate fluctuations.

Industry Context

This announcement reflects a positive trend in the medical device industry, particularly in the thrombectomy sector, where Penumbra is a leading player. The strong growth in U.S. thrombectomy sales indicates a growing demand for these types of medical procedures and devices.

Comparison to Industry Standards

• Penumbra's 21.2% growth in U.S. thrombectomy revenue is strong compared to other medical device companies, such as Stryker and Medtronic, which have reported single-digit growth in their respective neurovascular divisions.
• The 32% growth in the U.S. VTE franchise is particularly notable, as it indicates a successful expansion into a high-growth area of the market.
• Penumbra's adjusted EBITDA margin of 18.8% is competitive with other medical device companies, such as Boston Scientific, which has reported similar margins in recent quarters.
• The company's reiteration of its full-year revenue guidance suggests confidence in its ability to maintain its growth trajectory, which is a positive sign for investors.

Stakeholder Impact

• Shareholders will likely react positively to the strong revenue growth and increased guidance.
• Employees may benefit from the company's growth and success.
• Customers, including healthcare providers, hospitals, and clinics, will have access to innovative medical technologies.
• Suppliers may see increased demand for their products and services.
• Creditors may view the company as a lower-risk borrower due to its strong financial performance.

Next Steps

• Penumbra will host a conference call to discuss the third quarter 2024 financial results on October 30, 2024, at 4:30 PM Eastern Time.
• The company will continue to focus on developing innovative technologies for challenging medical conditions.

Key Dates

Keywords

thrombectomy, medical devices, revenue growth, VTE, embolization, financial results, EBITDA, healthcare, gross margin, operating expenses